What is a Clinical Pathway Handbook for Hyperbilirubinemia?
What was originally developed as a Quality-Based Procedure (QBP) for Hyperbilirubinemia has been revised and updated into a best evidence Clinical Pathway for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks).
Objectives
The key objectives of the Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (≥ 35 weeks) are to:
- Ensure all newborns receive bilirubin screening between 24-72 hours of life (if not clinically indicated and performed earlier)
- Ensure infants receive systematic bilirubin monitoring as per the treatment graph and risk nomograms recommended by evidence-based guideline
- Utilize health care resources responsibly through avoidance of unnecessary/excessive testing, timely discharge, appropriate outpatient follow-up and minimization of preventable readmission
- Reduce the incidence of severe hyperbilirubinemia and acute bilirubin encephalopathy
Resources
Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks)
A revised and updated version of the QBP for Hyperbilirubinemia.
A brief update of the changes made to the Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks).
Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks) Clinical Pathway Toolkit
An abridged version of the Clinical Pathway Handbook focusing on the clinical pathway.
QBP for Hyperbilirubinemia – Webinar Slides
Previously offered February 21st, 2014 and March 4th, 2014.
QBP for Hyperbilirubinemia – Webinar Q & A
This document was developed based on questions from the February 21st, 2014 and March 4th 2014 webinar sessions.